Mouse coagulation factor Ⅷ(FⅧ) ELISA Kit

Code CSB-E13084m
Size 96T,5×96T,10×96T How to order?
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Mouse Coagulation factor VIII (F8) ELISA Kit was designed for the quantitative measurement of Mouse Coagulation factor VIII (F8) protein in serum, plasma. It is a Sandwich ELISA kit, its detection range is 0.312 ng/mL-20 ng/mL and the sensitivity is 0.078 ng/mL.

Target Name coagulation factor VIII, procoagulant component
Alternative Names F8 ELISA kit; Cf8 ELISA kit; F8cCoagulation factor VIII ELISA kit; Procoagulant component ELISA kit
Abbreviation F8
Uniprot No. Q06194
Species Mus musculus (Mouse)
Sample Types serum, plasma
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.078 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of mouse FⅧ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1000Average %95
Range %89-99
1:2000Average %96
Range %92-101
1:4000Average %99
Range %94-102
1:8000Average %93
Range %86-97
The recovery of mouse FⅧ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 8680-92
EDTA plasma (n=4)9288-96
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
202.564 2.487 2.526 2.381
102.117 2.254 2.186 2.041
51.575 1.667 1.621 1.476
2.51.065 1.074 1.070 0.925
1.250.605 0.622 0.614 0.469
0.6250.332 0.344 0.338 0.193
0.3120.238 0.232 0.235 0.090
00.146 0.144 0.145
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.
Gene References into Functions
  1. Haemophilic animals (F8(-/-) mice) fed a high fat/fructose diet are highly prone to hepatic steatosis and thrombocytopenia. PMID: 29656466
  2. CD32 blockade suppresses the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific memory B-cells and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4(+) T cells. PMID: 28492697
  3. Type 2N von Willebrand disease variants were associated with decreased VWF secretion and impaired factor VIII binding/stability. PMID: 28581694
  4. Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days. PMID: 28561280
  5. results revealed localized vascular expression of FVIII and von Willebrand factor and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues. PMID: 27207787
  6. the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor masks the reducing effect of mutations in the C domains on factor VIII immunogenicity. PMID: 27758819
  7. Describe a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene. PMID: 26588198
  8. data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice PMID: 26668132
  9. Both platelet-VWF and plasma-VWF are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors. PMID: 25955153
  10. These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings. PMID: 25315236
  11. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. PMID: 25911555
  12. Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors. PMID: 25224783
  13. This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 cluster III. PMID: 25486042
  14. a fragment containing only approximately 20% of the VWF sequence is sufficient to support FVIII stability in vivo PMID: 24850761
  15. Endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse. PMID: 24719406
  16. Endothelial cells are the predominant, and possibly exclusive, source of plasma FVIII. PMID: 24705491
  17. Micro-computed tomography analysis of distal tibia metaphyses also revealed for the first time a major impact of the FVIII/thrombin/PAR1 axis on the dynamic bone structure, showing reduced bone. PMID: 23982175
  18. Findings indicate that improving protein trans-splicing by inter-chain disulfide bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer. PMID: 23526393
  19. Acute elevations in FVIII levels result in a non-linear thrombogenic effect, with non-significant increases in thrombogenic risk. Prolonged elevation of plasma FVIII did not further increase the thrombogenic potential of elevated FVIII levels. PMID: 23178924
  20. Transient B cell depletion and even more so use of a codon-optimized FVIII sequence in hepatic gene transfer represent promising strategies to avoid inhibitor formation and promote tolerance in gene therapy for hemophilia A. PMID: 22655063
  21. In this mouse model of venular thrombosis, partial FVIII inhibition yielded similar antithrombotic effects as nearly complete FVIII inhibition. PMID: 21777952
  22. Murine models of combined TFPI and factor VIII deficiency were used to examine the impact of TFPI deficiency on bleeding and clotting in hemophilia PMID: 22355108
  23. Compared with control mice, elevated FVIII stabilized thrombi (fewer emboli) after short injury, but it had no effect after longer injury. PMID: 21828144
  24. analysis of animal models for hemophilia A and the advantage of rats over mice in the factor VIII gene mutation model PMID: 20626616
  25. Expression of human B-domain deleted FVIII in the vascular endothelium of FVIII-deficient mice results in costorage of FVIII and von Willebrand factor in endothelial Weibel-Palade bodies and restores normal levels and activity of FVIII in plasma. PMID: 20606161
  26. The study presents the spectrum of factor VIII mutations in Korean patients with severe hemophilia A. PMID: 20533009
  27. FVIII-deficient mouse had a prolonged blood clotting time and their phenotypes are similar to human with hemophilia A. PMID: 20140858
  28. Factor VIII mRNA is expressed in liver sinusoid endothelium, hepatocytes, and kidney. PMID: 11583319
  29. Factor VIII binding site for ESH8 determined. PMID: 12011059
  30. Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure PMID: 12070019
  31. decrease in fVIII is not secondary to loss of von Willebrand factor in fulminant hepatic failure in mice PMID: 12730105
  32. findings suggest that a major T-cell epitope in the F8 C2 domain recognized by hemophilic mice is located within the same region that binds to inhibitors, vWF, and activated membranes PMID: 15351848
  33. FVIII's interaction with VWF and its intracellular transportation, storage, and secretion differ greatly depending on the cell type PMID: 15731176
  34. Gene therapy using this obviates the effect of desmopressin with hemophilia A. PMID: 15837921
  35. activation of the intrinsic pathway of coagulation is potently proatherogenic at the early stage of atherogenesis PMID: 15920033
  36. FVIII deficiency slightly modifies host defense in septic peritonitis in mice, but does not influence the final outcome of peritonitis. PMID: 16359511
  37. document crucial roles for von Willebrand factor and FVIII in experimental thrombosis under venous flow conditions in vivo PMID: 17119108
  38. VWF and latent TGF-beta1 present in plasma-derived FVIII preparations reduce the immune response against FVIII PMID: 17376515
  39. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice. PMID: 19132238
  40. FVIII-pulsed dendritic cells reduce anti-FVIII antibody formation in hemophilia A mice by induction of regulatory T-cell-mediated hyporesponsiveness of T-helper cells to FVIII. PMID: 19463774

Show More

Hide All

Subcellular Location Secreted, extracellular space.
Protein Families Multicopper oxidase family
Tissue Specificity Found in most tissues.
Database Links

KEGG: mmu:14069

STRING: 10090.ENSMUSP00000033539

UniGene: Mm.1805

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1